Compare iShares S&P GSCI Commodity-Indexed Trust ETF (GSG) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares S&P GSCI Commodity-Indexed Trust ETF vs Travere Therapeutics Inc. Common Stock — how do they compare? iShares S&P GSCI Commodity-Indexed Trust ETF trades at $36.59 (market cap $1.04B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Travere Therapeutics Inc. Common Stock is far larger — about 4.7× iShares S&P GSCI Commodity-Indexed Trust ETF's market cap, and iShares S&P GSCI Commodity-Indexed Trust ETF is trading nearer its 52-week high, Travere Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares S&P GSCI Commodity-Indexed Trust ETF for 40 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| GSG | TVTX | |
|---|---|---|
Market Cap | $1.04B | $4.88B |
Volume | 1,727,795 | 1,668,577 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $37.15 | $67.52 |
52-Week Low | $22.48 | $26.79 |
Typical Hold Time | 40 Days | 0 Days |
Enterprise Value | — | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSG trades at $36.77, up 0.96% with strong bullish technical signals from moving averages. The ETF shows volatile fundamentals with 2024 revenue of $51.25M and net income of $69.99M, though historical trends reveal significant profit margin swings from -126.61% in 2023 to 136.56% in 2024. Recent media coverage highlights commodity-focused positioning with energy exposure driving performance.
Outlook remains cautiously optimistic given bullish technical indicators and commodity market strength, but investors face volatility risks from energy sector exposure and geopolitical factors. The ETF's performance is heavily tied to broader commodity cycles, requiring careful monitoring of energy markets and global economic conditions.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares S&P GSCI Commodity-Indexed Trust ETF
GSG is a diversified commodity ETF that tracks the S&P GSCI Total Return Index. It provides exposure to a broad basket of futures, including energy, metals, and agriculture, with a significant weighting toward the energy sector.
Read more on GSG →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
